stockrowEnsysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024.
- Revenue
- −15.1%
- EPS
- +74.7%
- Free cash flow
- +27.5%
Quarter to June 2026, against a year earlier
Follow ENSC
Alert me
Ensysce Biosciences, Inc. (ENSC) EV/Sales
As of 6 November 2026, Ensysce Biosciences, Inc. (ENSC) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from −0.9× (December 2022) to 81.4× (July 2021); the current reading is higher than 71% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.2× | — |
| FY2024 | 0.6× | (51.13%) |
| FY2023 | 1.2× | — |
| FY2022 | −0.2× | — |
| FY2021 | 24.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | 8.96% |
| Mar 2026 | 0.8× | — |
| Dec 2025 | −0.2× | — |
| Sep 2025 | 1.3× | 181.39% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −6.4× |
| SNGX Soligenix Inc. compare | −4.1× |
| IMRN IMMURON compare | −3.5× |
| KPRX Kiora Pharmaceuticals, Inc. compare | −0.4× |
| MTVA MetaVia Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| SYBX Synlogic, Inc. compare | 0.1× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.0× |
| ENSC Ensysce Biosciences, Inc. | 1.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)